Table 3.
Comparison of Baseline Characteristics Between Patients With and Without Changes in PA Screening After MRA Initiation
| A. Patients with positive PA screening at baseline | |||
|---|---|---|---|
| PA screening after MRA use | |||
| Variable | Negative | Persistent positive | P value |
| n | 45 | 49 | |
| Age (years) | 56 [47, 66] | 57 [47, 64] | .97 |
| Sex (n men, %) | 30 (66.7) | 29 (59.2) | .45 |
| BMI (kg/m2) | 34.7 [29.7, 38.8] | 32.6 [28.8, 36.2] | .12 |
| SBP (mm Hg) | 158 [143, 175] | 146 [122, 159] | .01 |
| DBP (mm Hg) | 88 [80, 98] | 81 [70, 88] | .003 |
| eGFR (mL/min/1.73 m2) | 88 [67, 101] | 81 [56, 90] | .44 |
| Serum potassium (mM) | 3.7 [3.5, 4.3] | 3.7 [3.5, 4.0] | .09 |
| PAC (ng/dL) | 18.8 [15.6, 27.3] | 24.1 [19.2, 32.4] | .03 |
| PRA (ng/mL/h) | 0.3 [0.1, 0.6] | 0.2 [0.1, 0.6] | .25 |
| DRC (pg/mL) | 2.1 [2.1, 5.1] | 2.1 [2.1, 3.2] | .69 |
| ARR (ng/dL per ng/mL/h) | 57.3 [35.8, 110.4] | 100.3 [42.5, 216.2] | .04 |
| PA cases (n, %) | 32 (71.1) | 45 (91.8) | .009 |
| Antihypertensive agents (n) | 3.0 [2.0, 4.0] | 3.0 [2.0, 4.0] | .25 |
| Beta-blocker (n, %) | 24 (53.3) | 39 (79.6) | .007 |
| MRA dose (mg/day) | 25.0 [25.0, 75.0] | 25.0 [25.0, 50.0] | .03 |
| MRA dose per body weight (mg/kg) | 0.37 [0.24, 0.67] | 0.29 [0.21, 0.48] | .06 |
| Duration of MRA treatment (days) | 113 [54, 330] | 101 [42, 204] | .26 |
| B. Patients with negative PA screening at baseline | |||
| Variable | Positive | Persistent negative | P value |
| n | 9 | 43 | |
| Age (years) | 51 [38, 67] | 55 [48, 64] | .75 |
| Sex (n men, %) | 3 (33.3) | 14 (32.6) | .96 |
| BMI (kg/m2) | 30.7 [28.9, 32.7] | 31.5 [27.2, 36.7] | .61 |
| SBP (mm Hg) | 164 [139, 174] | 150 [135, 171] | .59 |
| DBP (mm Hg) | 76 [75, 98] | 78 [70, 88] | .61 |
| eGFR (mL/min/1.73 m2) | 94 [58, 97] | 82 [73, 100] | .77 |
| Serum potassium (mM) | 3.4 [2.9, 4.0] | 4.1 [3.8, 4.4] | .009 |
| PAC (ng/dL) | 15.0 [9.7, 17.0] | 12.2 [6.7, 21.7] | .65 |
| PRA (ng/mL/h) | 1.0 [0.8, 1.1] | 1.0 [0.6, 3.6] | .57 |
| DRC (pg/mL) | 6.3 [3.0, 10.2] | 9.8 [6.6, 22.2] | .32 |
| ARR (ng/dL per ng/mL/h) | 16.0 [13.8, 23.1] | 11.4 [5.2, 19.4] | .12 |
| PA cases (n, %) | 5 (55.6) | 9 (20.9) | .03 |
| Antihypertensive agents (n) | 3.0 [1.8, 3.3] | 2.0 [1.0, 3.8] | .97 |
| Beta-blocker (n, %) | 6 (66.7) | 20 (46.5) | .27 |
| MRA dose (mg/day) | 50.0 [25.0, 50.0] | 25.0 [25.0, 50.0] | .49 |
| MRA dose per body weight (mg/kg) | 0.48 [0.36, 0.75] | 0.40 [0.23, 0.65] | .39 |
| Duration of MRA treatment (days) | 111 [91, 205] | 79 [46, 150] | .054 |
Abbreviations: ARR = aldosterone/renin ratio; BMI = body mass index; DBP = diastolic blood pressure; DRC = direct renin concentration; eGFR = estimated glomerular filtration rate; MRA = mineralocorticoid receptor antagonist; PA = primary aldosteronism; PAC = plasma aldosterone concentration; PRA = plasma renin activity; SBP = systolic blood pressure.
Data are shown as median [interquartile range] or number (n) and %. Comparisons between groups were performed using the Mann Whitney U test for continuous variables or Chi-squared or Fisher’s exact test for categorical variables.